TP53 and acute myeloid leukemia: Combined treatment with AZA and eprenetapopt has been recently reported to yield high rates of clinical responses and molecular remissions in patients with TP53-mutant MDS and AML.157 Whether or not these novel therapies would be able to transform some elderly patients with AML into potential candidates for alloHSCT remains to be seen in the future.